InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Enters Strategic Drug Development Agreement with Catalent Inc. (NYSE: CTLT)
Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, today announced its entry into a drug development agreement with Catalent (NYSE: CTLT), the leading global provider of advanced delivery technologies, development and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. According to the update, Cybin will be applying Catalent’s proprietary Zydis(R) orally disintegrating tablet (“ODT”) technology…